• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medtronic plans to bring next-gen diabetes tech to FDA this fiscal year, no spinoff planned

November 23, 2021 By Sean Whooley

Medtronic MiniMed 780G
The Medtronic MiniMed 780G system. [Image from Medtronic]
Medtronic (NYSE:MDT) confirmed that it anticipates major regulatory steps for its next-generation insulin pump and sensor during this fiscal year.

Medtronic’s fiscal years wrap up at the end of April.

Speaking on the company’s second-quarter earnings call, Chair & CEO Geoff Martha said Medtronic expects its MiniMed 780G insulin pump system with the Guardian 4 sensor for continuous glucose monitoring (CGM) to drive growth once approved, with the company currently in talks with the FDA.

“We’ve got a really strong uptake of 780G and Guardian 4 outside the U.S. and inside the U.S., we’re waiting for that approval to come through,” Medtronic EVP & President of its Diabetes Operating Unit and Cardiovascular Portfolio Sean Salmon said on the call. “We’re making progress with the FDA.”

Previous generations of MiniMed insulin pumps have come under scrutiny. Still, Medtronic as recently as last month touted one-year clinical data for the next-generation MiniMed 780G with Guardian 3 in children. Company officials expect Guardian 4 to deliver positive outcomes as well.

Additionally, Martha touched on the Simplera disposable CGM sensor (formerly Synergy), which he touted as half the size of the Guardian 4 sensor. The company expects to bring the Simplera sensor to the FDA later this fiscal year.

Finally, when asked by an analyst if Medtronic had any plans to spinoff its diabetes business, Martha said there are no current plans, but the executive committee at the medtech giant is spending “a lot more time” looking at portfolios and capital allocation to “make sure we’re the right owner.”

“I do see opportunities,” Martha said. “I’m not signaling anything, but I can tell you this is something we’re constantly looking at. I don’t see ourselves as [General Electric] or [Johnson & Johnson] with dramatically different businesses, but I do believe it is an opportunity over time.”

Filed Under: Auto-injectors, Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring Tagged With: Medtronic

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS